Journals / İnfeksiyon Dergisi / 2005 / Cilt: 19 - Sayı: 1

Investigation of the prevalance and antibiotic susceptibility of extended spectrum beta-lactamase producing bacilli in blood culture specimens

Kan kültürü örneklerinde genişlemiş spektrumlu beta-laktamaz üreten enterik basillerin prevalensı ve antibiyotik duyarlılıklarının araştırılması

Pages
111–114
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results indicate that the ESBL production of enteric bacilli isolated from blood samples is markedly high and meropenem is the most active agent against ESBL producing organisms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The purpose of this study was to determine the prevalence of ESBL production in enteric bacilli isolated from blood culture specimens and to determine antibiotic susceptibilities'of ESBL producing microorganisms.
📊
Key Findings & Data:The study included 166 enteric bacilli isolated from 7856 blood culture samples.
💡
Conclusion & Impact:The results indicate that the ESBL production of enteric bacilli isolated from blood samples is markedly high and meropenem is the most active agent against ESBL producing organisms.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The purpose of this study was to determine the prevalence of ESBL production in enteric bacilli isolated from blood culture specimens and to determine antibiotic susceptibilities'of ESBL producing microorganisms. The production of ESBL was determined with double disk synergy test and E-test method and the antibiotic susceptibilities of ESBL producing organisms were investigated with E-test. The study included 166 enteric bacilli isolated from 7856 blood culture samples. Of the enteric bacilli 35 % were ESBL producers. The antibiotic susceptibilities of the ESBL producing organisms were found as 100% for meropenem, 91% for isepamicin, 89% for amikacin, 64% for ciprofloxacin, 50% for piperacillin-tazobactam, 36% for trimetophrim-sulfomethoxasole and 19% for amoxycillin-clavulanic acid. The results indicate that the ESBL production of enteric bacilli isolated from blood samples is markedly high and meropenem is the most active agent against ESBL producing organisms.

Özet

Bu çalışmada, kan kültürlerinden soyutlanan enterik basillerin genişlemiş spektrumlu beta-laktamaz (GSBL) üretme sıklığı ve GSBL üreten mikro-organizmaların antibiyotik duyarlılıklarının saptanması amaçlandı. Enterik basillerin GSBL üretimi çift disk sinerji ve E-test yöntemi, antibiyotik duyarlılıkları ise E-test yöntemi ile araştırıldı. İncelenen 7856 kan kültürü örneğinden 166 enterik basil soyutlandı ve bunların %35'inin GSBL ürettiği belirlendi. Genişlemiş spektrumlu beta-laktamaz üreten bakterilerin antibiyotik duyarlılıkları; meropenem %100, isepamisin %91, amikasin %89, siprofloksasin %64, piperasilin-tazobaktam %50, trimetoprim-sulfametoksazol %36 ve amoksisilin-klavulanik asit %19 olarak saptandı. Kan kültürü örneklerinden soyutlanan enterik basillerin GSBL üretim sıklığının yüksek olduğu ve bu şuşlara karşı en etkili antibiyotiğin meropenem olduğu gözlendi.

🔖

Cite This Article

YAKUPOĞULLARI, Y., KİZİRGİL, A., TORAMAN, A. Z., ŞENOL, F. F. (2022). Investigation of the prevalance and antibiotic susceptibility of extended spectrum beta-lactamase producing bacilli in blood culture specimens. İnfeksiyon Dergisi, Cilt: 19 - Sayı: 1, 111–114. https://ajindex.com/articles/546520

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Mayer KH, Opal SM, Medeiros AA. Mechanisms of antibiotic resistace. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995: 212-25
  2. Livermore DM. Detection of beta-lactamase mediated resistance. J Antimicrob Chemother 2001; 48 (Suppl 1): 59-64
  3. NCCLS. Performance Standards for Antimicrobial Susceptibility Testing. Tenth Informational Supplement. NCCLS document M100-s10. Wayne, Pennsylvania: NCCLS, 2000
  4. Özsoy MF, Öncül O, Yıldırım A, Pahsa A. Genişlemiş spektrumlu beta-laktamazlar: klinik önemi ve getirdiği sorunlar. Flora 2001; 6 (Ek 1): 3-23
  5. Patterson JE. Antibiotic utilization. Is there an effect on antimicrobial resistance. Chest 2001; 2 (Suppl): 426-30
  6. Rahal JJ. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial klebsiella. JAMA 1998; 280: 1233-7
  7. Gültekin M, Öğünç D, Günseren F, Çolak D, Kırbaş İ, Mamıkoğlu L. Hastane infeksiyonu etkeni Klebsiella pneumoniae ve Escherichia coli suşlarının genişlemiş spektrumlu beta-laktamaz ve antibiyotik duyarlılık özelliklerinin araştırılması. İnfek Derg 1999; 13: 515-20
  8. Quinn JP. Clinical significiance of extended spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 1994; 13 (Suppl 1): 39-42
  9. Kim NB, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 2002; 52: 99-106
  10. Demirdağ K, Kizirgil A, Özden M, Kalkan A, Felek S, Toraman ZA. Hastane ve toplum kökenli Klebsiella pneumoniae ve Escherichia coli suşlarında genişlemiş spektrumlu beta-laktamaz sıklığının araştırılması. ANKEM Derg 2001; 15: 748-52
  11. Gulay Z, Thomson CJ, Yuluğ N, Amyes SG. High prevalence of ESBL among Klebsiella pneumoniae strains isolated at an university hospital in Turkey. J Chemother 2000; 12: 145-52
  12. Durmaz R, Durmaz B, Koroglu M, Tekerekoglu MS. Detection and typing of extended-spectrum beta-lactamases in a clinical isolates of family Enterobacteriaceae in a medical center in Turkey. Microb Drug Resist 2001; 7: 171-5
  13. Babini GS, Livermore DM. Antimicrobial resistance among Klebsiella spp collected from intensive care unites in Southern and Western Europe in 1997-98. J Antimicrob Chemother 2000; 45: 183-9
  14. Livermore DM, Yuan M. Antibiotic resistance and production of ESBL among Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38: 409
  15. Peterson